Here’s Why Lucid Diagnostics (LUCD) Declined in Q3

1 week ago 7

Soumya Eswaran

Wed, December 24, 2025 astatine 6:45 AM CST 3 min read

Minot Light Capital Partners, an concern absorption company, released its Q3 2025 concern letter. A transcript of the missive tin beryllium downloaded here. In the quarter, Minot Light generated coagulated returns for constricted partners, with a nett of 7.6%. However, connected a nett basis, the show underperformed the benchmarks, peculiarly the micro-cap benchmark’s 17.1% return. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Minot Light Capital Partners highlighted stocks specified arsenic Lucid Diagnostics Inc. (NASDAQ:LUCD). Lucid Diagnostics Inc. (NASDAQ:LUCD) is simply a US-based commercial-stage aesculapian diagnostics exertion company. The one-month instrumentality for Lucid Diagnostics Inc. (NASDAQ:LUCD) was 0.92%, and its shares gained 43.92% implicit the past 52 weeks. On December 23, 2025, Lucid Diagnostics Inc. (NASDAQ:LUCD) banal closed astatine $1.10 per share, with a marketplace capitalization of $144.209 million.

Minot Light Capital Partners stated the pursuing regarding Lucid Diagnostics Inc. (NASDAQ:LUCD) successful its 3rd 4th 2025 capitalist letter:

"Lucid Diagnostics Inc. (NASDAQ:LUCD): The 2nd biggest detractor successful our portfolio this 4th was Lucid Diagnostics. Lucid presently markets an FDA-approved DNA trial for the aboriginal detection of esophageal precancer and cancer, known arsenic EsoGuard. We judge EsoGuard has a morganatic multi-billion dollar positive marketplace accidental owed to its unsocial capabilities, outstanding objective information and attractiveness arsenic a minimally invasive trial for nonendoscopic precancer testing. The diligent request for this trial is large, the company’s objective information is strong, and it has a unsocial presumption successful the marketplace. The lone happening holding backmost accelerating adoption has been a deficiency of reimbursement.